Microcarrier Cell Culture Harvest Timing Patents: Leaders & White Space 2026
Microcarrier Cell Culture Harvest Timing Patents: Who Holds the Claims
58 published records sit across a narrow IPC footprint dominated by C12N (79.3%) and C12M (72.4%), meaning most claims are written as biology or apparatus, not as software or imaging. Filings rose from 3 in 2017 to a peak of 14 in 2022, then declined to 2 by 2024 — a 50% drop from the 2021 level of 4 over that three-year span. 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a trend reversal or a continued fall.
- 1CELLINO BIOTECH INC23
- 2GENZYME CORP14
- 3THE IMMUNE RESPONSE CORP INC7
- 4GLOBAL LIFE SCIENCES SOLUTIONS USA LLC6
- 5CORNING INC3
See the full microcarrier cell culture harvest timing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents on microcarrier cell culture harvest timing?
The assignee ranking for this dataset covers 19 companies, and the leader holds 23 of the 58 published records in scope — well ahead of fifth place, which holds 3. That gap points to a single organisation running a sustained, multi-year filing program around harvest-timing signals such as viability decline and product titer, while most other ranked entrants filed only a handful of times. It does not mean that one company controls the whole field, since the ranking only reflects records matching this specific search and IPC scope.
Is patent filing in this area growing or slowing down?
Filings rose from 3 in 2017 to a peak of 14 in 2022, then fell to 2 by 2024 — a 50% decline from the 2021 level of 4. Because patent publication typically lags actual filing by around 18 months, the 2025 and 2026 counts in this dataset are still incomplete and should not yet be read as confirmation of a continued decline. The honest read through the last complete year, 2024, is a cool-down from a 2022 peak, not a dead field.
What technology areas dominate the IPC classification in this space?
C12N (microorganisms and genetic engineering) and C12M (bioreactors and enzyme apparatus) are the two dominant subclasses, covering 79.3% and 72.4% of the 58 records in scope respectively. Analytical and imaging-related classes — B01L, G01N and G06T — each sit near a third of records, while peptide and fermentation classes (C07K, C12P) appear in a smaller minority. Since a single record can carry several IPC classes, these percentages add up to more than 100% and should not be treated as mutually exclusive shares of one whole.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Microcarrier Cell Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.